2. Induced Disease Models Products Metabolic Enzyme/Protease Neuronal Signaling GPCR/G Protein Autophagy
  3. Cardiovascular System Disease Models Endogenous Metabolite Adrenergic Receptor Autophagy
  4. Heart Disease Models
  5. Norepinephrine

Norepinephrine  (Synonyms: Levarterenol; L-Noradrenaline)

Cat. No.: HY-13715 Purity: 99.33%
COA Handling Instructions

Molarity Calculator

Norepinephrine (Levarterenol; L-Noradrenaline) is a potent adrenergic receptor (AR) agonist. Norepinephrine activates α1, α2, β1 receptors.

For research use only. We do not sell to patients.

Norepinephrine Chemical Structure

Norepinephrine Chemical Structure

CAS No. : 51-41-2

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
100 mg USD 50 In-stock
500 mg USD 140 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 29 publication(s) in Google Scholar

Other Forms of Norepinephrine:

Norepinephrine Related Antibodies

Top Publications Citing Use of Products

    Norepinephrine purchased from MedChemExpress. Usage Cited in: Cardiovasc Res. 2018 Feb 1;114(2):300-311.  [Abstract]

    Knockdown of GATA4 ameliorated morphology and functional changes in a Meox1 cell line with NE stimulation. Immunodetection of actin in HL-1 cells. Actin staining appeared green, and sections are counterstained blue with DAPI (40,6-diamidino-2-phenylindole).

    Norepinephrine purchased from MedChemExpress. Usage Cited in: J Nutr Biochem. 2018 May 1;58:110-118.  [Abstract]

    PASMCs are pretreated with or not Norepinephrine (50 μM) or ICI 118,551 (5 nM), and α-SMA (D) are analyzed.

    View All Adrenergic Receptor Isoform Specific Products:

    View All Isoforms

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Norepinephrine (Levarterenol; L-Noradrenaline) is a potent adrenergic receptor (AR) agonist. Norepinephrine activates α1, α2, β1 receptors[1][2][3][4].

    IC50 & Target[1][2]

    α1-adrenergic receptor

     

    α2-adrenergic receptor

     

    Beta-1 adrenergic receptor

     

    Microbial Metabolite

     

    Human Endogenous Metabolite

     

    In Vitro

    Norepinephrine (NE) is generally considered to be a β1-subtype selective adrenergic agonist over β2-adrenoceptor. Norepinephrine(NE) also has direct activity at the β2-adrenoceptor in higher concentrations[1].
    Adipocytes from the inguinal fat pad (iWA) or the interscapular fat pad (BA) are isolated from neonatal wild-type C57BL/6J mice and cultured. To examine the effect of activating AT2 upon β-adrenergic signaling, cAMP production is first assessed in response to Norepinephrine (NE, 10 μM) with or without CGP (10 nM) co-treatment.
    Norepinephrine (NE) increases cAMP as expected in iWA, and CGP does not alter this effect
    Norepinephrine (NE) is also known to induce lipolysis, and liberated fatty acids are required to functionally activate UCP1 protein and to stimulate heat production. CREB phosphorylation at Ser133 is increased after Norepinephrine (NE) treatment and significantly attenuated with CGP co-treatment in mouse iWA[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Norepinephrine Related Antibodies
    In Vivo

    Norepinephrine (NE) is generally considered to be a β1-subtype selective adrenergic agonist over β2-adrenoceptor. Norepinephrine(NE) also has direct activity at the β2-adrenoceptor in higher concentrations[1].
    Adipocytes from the inguinal fat pad (iWA) or the interscapular fat pad (BA) are isolated from neonatal wild-type C57BL/6J mice and cultured. To examine the effect of activating AT2 upon β-adrenergic signaling, cAMP production is first assessed in response to Norepinephrine (NE, 10 μM) with or without CGP (10 nM) co-treatment.
    Norepinephrine (NE) increases cAMP as expected in iWA, and CGP does not alter this effect
    Norepinephrine (NE) is also known to induce lipolysis, and liberated fatty acids are required to functionally activate UCP1 protein and to stimulate heat production. CREB phosphorylation at Ser133 is increased after Norepinephrine (NE) treatment and significantly attenuated with CGP co-treatment in mouse iWA[3].

    Induction of cardiomyopathy[5][6]
    Background
    Norepinephrine is a potent growth factor for cardiomyocytes, and long-term infusion of sub-hypertensive doses of Norepinephrine in animals can cause an increase in myocardial mass and left ventricular wall thickness. Norepinephrine activates the raf-1 kinase/MAP kinase cascade through α1 and β-adrenergic stimulation, and the signaling pathways from these two receptors work synergistically to induce cardiomyocyte hypertrophy.
    Specific Mmodeling Methods
    Rat: Spragues-Dawley rats • adult (6 months old) • Male &bull.
    Administration: Each rat was continuously injected with 100 μg/kg/h or 200 μg/kg/h through an osmotic minipump.
    Note
    Modeling Indicators
    Molecular changes: Significantly increased Dnmt activity and the expressions of Dnmt1, 3a, and 3b in the left ventricle.
    Significantly increased the mRNA expressions of fetal genes ANP, BNP, and βMHC in the left ventricle.
    Significantly increased ROS production in the left ventricle and increased global genomic DNA methylation and gene-specific CpG methylation at the Egr-1 binding site of the left ventricular PKCε promoter region in a concentration-dependent manner.
    Increased lactate dehydrogenase release in a concentration-dependent manner.
    Significantly reduced the left ventricular developed pressure and dP/dtmax, inducing the upregulation of myotrophin and downregulation of four-and-a-half LIM domains protein 2 (FHL2).
    Phenotype observations: Increased the myocardial infarction area and sustained the elevation of blood pressure.
    Induced cardiac hypertrophy and reduced cardiac contractility.
    Increased the left ventricular weight.
    Correlated Product(s)
    Opposite Product(s) 5-Aza-2’-deoxycytidine (HY-A0004), Prazosin (HY-B0193), Propranolol (HY-B0573B)

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    Molecular Weight

    169.18

    Formula

    C8H11NO3
    CAS No.
    Appearance

    Solid

    Color

    White to yellow

    SMILES

    OC1=CC=C([C@@H](O)CN)C=C1O
    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    4°C, protect from light, stored under nitrogen

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

    Solvent & Solubility
    In Vitro: 

    DMSO : 50 mg/mL (295.54 mM; ultrasonic and adjust pH to 2 with HCl; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : ≥ 1.69 mg/mL (9.99 mM)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 5.9109 mL 29.5543 mL 59.1086 mL
    5 mM 1.1822 mL 5.9109 mL 11.8217 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (12.29 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (12.29 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.33%

    COA (246 KB) HNMR (250 KB) LCMS (86 KB)

    Handling Instructions (2659 KB)
    References
    Cell Assay
    [2]

    Subcutaneous preadipocytes derived from a 38-year old non-diabetic female donor are immortalized with TERT and HPV E6/E7. For the current studies, a stable diploid clone (referred to as clone B) with consistent differentiation capacity is isolated by ring cloning. Cells are grown in preadipocyte PGM2 media. Once cells are confluent, differentiation is induced by incubation in differentiation media consisting of dexamethasone, IBMX, indomethacin, and additional insulin. Cells are differentiated for 10 days. Prior to treatment, media is replaced with PGM2 media for one day and then switched to serum-free media overnight for treatments. Adipocytes are treated for 6 hours with vehicle, Norepinephrine (NE, 10 μM), CGP (10 nM), or Norepinephrine (NE) and CGP[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    H2O / DMSO 1 mM 5.9109 mL 29.5543 mL 59.1086 mL 147.7716 mL
    5 mM 1.1822 mL 5.9109 mL 11.8217 mL 29.5543 mL
    DMSO 10 mM 0.5911 mL 2.9554 mL 5.9109 mL 14.7772 mL
    15 mM 0.3941 mL 1.9703 mL 3.9406 mL 9.8514 mL
    20 mM 0.2955 mL 1.4777 mL 2.9554 mL 7.3886 mL
    25 mM 0.2364 mL 1.1822 mL 2.3643 mL 5.9109 mL
    30 mM 0.1970 mL 0.9851 mL 1.9703 mL 4.9257 mL
    40 mM 0.1478 mL 0.7389 mL 1.4777 mL 3.6943 mL
    50 mM 0.1182 mL 0.5911 mL 1.1822 mL 2.9554 mL
    60 mM 0.0985 mL 0.4926 mL 0.9851 mL 2.4629 mL
    80 mM 0.0739 mL 0.3694 mL 0.7389 mL 1.8471 mL
    100 mM 0.0591 mL 0.2955 mL 0.5911 mL 1.4777 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Norepinephrine Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Norepinephrine51-41-2Levarterenol L-NoradrenalineEndogenous MetaboliteAdrenergic ReceptorAutophagyBeta Receptoradrenergic receptorα1α2β1Inhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email Address *

    Phone Number *

    		 

    Organization Name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Norepinephrine
    Cat. No.:
    HY-13715
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.